Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Marginal Zone Lymphoma (MZL): early-phase trial registry
3 of 5 indexed Marginal Zone Lymphoma (MZL) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Marginal Zone Lymphoma (MZL): 5 US clinical trials tracked, 3 recruiting.
Marginal Zone Lymphoma (MZL) is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Nurix Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition marginal-zone-lymphoma-mzl
OPEN 3 | RECR 60% | LATE 0 | EARLY 5 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
Marginal Zone Lymphoma (MZL) lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Marginal Zone Lymphoma (MZL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Marginal Zone Lymphoma (MZL) is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Marginal Zone Lymphoma (MZL) research.
Nurix Therapeutics accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Marginal Zone Lymphoma (MZL) enrolment sits around 248 participants.
Median target enrolment is 248 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Marginal Zone Lymphoma (MZL) research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
NCT05131022
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
NCT04830137
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics
NCT07121946
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Genmab
NCT03625037
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Calibr, a division of Scripps Research
NCT04450069
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Marginal Zone Lymphoma (MZL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Marginal Zone Lymphoma (MZL) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Marginal Zone Lymphoma (MZL) page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Marginal Zone Lymphoma (MZL) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nurix Therapeutics sponsors the most Marginal Zone Lymphoma (MZL) trials on record, review their full trial history before evaluating a specific study. See Nurix Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Marginal Zone Lymphoma (MZL) condition card totals 5 registered trials; most-linked intervention CLBR001 and SWI019; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.